| Quantity: | |
|---|---|
Broad model portfolio – Allergen (OVA, HDM, Fel d 1), adjuvant-combined (LPS, c-di-GMP), and TSLP-driven (MC903) models covering eosinophilic, neutrophilic, and mixed granulocytic asthma endotypes.
Multiple species/strains – BALB/c (Th2-prone), C57BL/6 (Th1/Th17-prone), and HIS humanized mice available.
Comprehensive endpoints – Body weight, airway hyperresponsiveness (Penh, resistance), BALF cell counts (eosinophils, neutrophils, macrophages), serum IgE/allergen-specific IgE, cytokine profiling (IL-4, IL-5, IL-13, IL-17), lung histopathology (HE, Masson, PAS), hematology.
Translational value – Ideal for testing biologics (anti-IL-4Rα, anti-IL-5, anti-IL-13), JAK inhibitors, corticosteroids, and bronchodilators.
IND-ready data packages – Studies can be conducted in accordance with GLP principles.
OVA Induced Asthma Model in C57BL/6 Mice
OVA Induced Asthma Model in BALB/c Mice
OVA Induced Asthma Model in HIS Mice
OVA+MC903 Induced Asthma Model in C57BL/6 Mice
OVA+LPS Induced Neutrophilic Asthma Model in C57BL/6 Mice
HDM Induced Asthma Model in C57BL/6 Mice
HDM Induced Asthma Model in IL4/IL4R Mice
HDM+LPS Induced Asthma Model in C57BL/6 Mice
HDM + c-di-GMP Induced Asthma Model in C57BL/6 Mice
Fel d 1 Induced Asthma Model in BALB/c Mice
• Efficacy testing of biologics (anti-IL-4Rα, anti-IL-5, anti-IL-13, anti-TSLP, anti-IL-33)
• Evaluation of small molecule inhibitors (JAK inhibitors, PDE4 inhibitors, CRTH2 antagonists)
• Target validation for Th2, Th17, and epithelial-derived cytokine pathways
• Biomarker discovery (IgE, cytokine signatures, eosinophil/neutrophil markers)
• IND-enabling pharmacology and toxicology studies
Parameter | Specificatio |
Species/Strain | Mouse (BALB/c, C57BL/6, HIS humanized) |
Induction method | OVA ± alum ± MC903 ± LPS; HDM ± c-di-GMP; Fel d 1 + alum |
Study duration | 3–8 weeks (sensitization + challenge phases) |
Key endpoints | Body weight, airway hyperresponsiveness (invasive/non-invasive), BALF cytology (eosinophils, neutrophils, macrophages), serum total IgE & allergen-specific IgE, cytokine levels (IL-4, IL-5, IL-13, IL-17, IFN-γ), lung histopathology (HE, Masson, PAS) with scoring, hematology (optional) |
Data package | Raw data, analysis reports, BALF cell counts, ELISA results, histology slides, lung function data, bioinformatics (optional) |
Q: How do I choose the right AD model for my drug candidate?
A: Consider your drug’s mechanism: Th2‑targeted biologics (e.g., anti‑IL‑4Rα) are best evaluated in hapten or MC903 models; Th17‑related compounds may be suited for IL‑36 or HDM+SEB models. BALB/c mice exhibit stronger Th2 responses, while C57BL/6 show more balanced Th1/Th17 profiles. Our scientific team can guide model selection based on your specific target.
Q: Can these models be used for IND‑enabling studies?
A: Yes. Studies can be conducted in accordance with GLP principles for regulatory submissions (FDA, EMA).
Q: Do you offer customized study protocols (e.g., different dosing schedules, combination therapies)?
A: Absolutely. Our scientific team tailors induction protocols, treatment schedules, and endpoint analyses to your specific drug candidate.
Q: What is the typical timeline for a pilot efficacy study?
A: Most AD models complete within 2–4 weeks, including sensitization/challenge and treatment phases. Specific timelines depend on model choice and endpoints.
